class 4 endemic disease designation for Covid-19 in Taiwan 結果共1筆

Taiwan has received 462,800 doses of Novavax’s XBB vaccine, with distribution starting on January 9, 2023, according to the Taiwan Centers for Diseases Control (CDC). In May of this year, Taiwan categorized Covid-19 as a class 4 endemic disease, similar to seasonal flu. The decision was based on clinical trial reports and immunization recommendations from the U.S., the European Union (EU), and the Advisory Committee on Immunization Practices (ACIP) of the Ministry of Health and Welfare (MOHW). Unvaccinated individuals are advised to receive two doses of 0.5mL each, administered at least four weeks apart. Those who have already received a COVID-19 vaccine should receive a single dose of 0.5mL, provided at least three months have passed since their last dose. The domestically available XBB vaccine includes those produced by Moderna and Novavax, and recipients can choose either brand for vaccination.